The FDA classed the recall as Class II on Oct. 10. The pharmacy had received an FDA warning letter in December 2025 over sterile production problems.
Recap by typeshit. Full story at USA TODAY.
A nationwide recall now covers a GLP-1 injectable. The full story names the affected medication and explains why it was pulled.
32:25
The channel walks through FDA inspection findings of mold at suppliers and what people taking GLP-1 medications should watch for.
A fresh warning points to more people ending up in hospital after taking peptides that aren't approved. Tap through for who issued it.
A local TV health segment on safety when using peptide therapy and GLP-1 drugs, aimed at men's health.
17:44
NP on a GLP draws on both her clinical work and her own time on the medication to cover what she thinks people starting a GLP-1 should know.
Staff at one plant hid documents and poured samples down sinks, inspection reports show. Both suppliers of compounded semaglutide and tirzepatide are now on FDA import alert.
Loading…